MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · IEX Real-Time Price · USD
3.060
0.00 (0.00%)
May 3, 2024, 3:33 PM EDT - Market open
MEI Pharma Revenue
MEI Pharma had revenue of $72.65M in the twelve months ending December 31, 2023, with 16.10% growth year-over-year. In the fiscal year ending June 30, 2023, MEI Pharma had annual revenue of $48.82M with 19.95% growth.
Revenue (ttm)
$72.65M
Revenue Growth
+16.10%
P/S Ratio
0.28
Revenue / Employee
$1,579,304
Employees
46
Market Cap
20.39M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 48.82M | 8.12M | 19.95% |
Jun 30, 2022 | 40.70M | 5.90M | 16.96% |
Jun 30, 2021 | 34.80M | 7.04M | 25.36% |
Jun 30, 2020 | 27.76M | 22.84M | 464.72% |
Jun 30, 2019 | 4.92M | 3.29M | 203.02% |
Jun 30, 2018 | 1.62M | -21.63M | -93.02% |
Jun 30, 2017 | 23.25M | - | - |
Jun 30, 2016 | 0 | - | - |
Jun 30, 2015 | 0 | - | - |
Jun 30, 2014 | 0 | - | - |
Jun 30, 2013 | 0 | - | - |
Jun 30, 2012 | 0 | - | - |
Jun 30, 2011 | 0 | - | - |
Jun 30, 2010 | 0 | - | - |
Jun 30, 2009 | 0 | - | - |
Jun 30, 2008 | 674.00K | 29.00K | 4.50% |
Jun 30, 2007 | 645.00K | 199.00K | 44.62% |
Jun 30, 2006 | 446.00K | 138.00K | 44.81% |
Jun 30, 2005 | 308.00K | 115.00K | 59.59% |
Jun 30, 2004 | 193.00K | 48.00K | 33.10% |
Jun 30, 2003 | 145.00K | 138.00K | 1,971.43% |
Jun 30, 2002 | 7.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Marpai | 37.16M |
DermTech | 15.30M |
Accelerate Diagnostics | 12.06M |
NeurAxis | 2.46M |
OncoCyte | 1.50M |
AIM ImmunoTech | 202.00K |
Alaunos Therapeutics | 5.00K |
MEIP News
- 22 days ago - MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 - Business Wire
- 22 days ago - MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients - Business Wire
- 23 days ago - MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum - Business Wire
- 5 weeks ago - MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia - Business Wire
- 2 months ago - Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire
- 2 months ago - MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
- 3 months ago - MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 - Business Wire
- 5 months ago - MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 - Business Wire